Radiopharm Theranostics (RAD) Reports $7.5M Quarter-End Cash and RAD101 Phase 3 Preparation

What happened

Radiopharm Theranostics reported $7.5M in cash at quarter-end, up from $4.1M in the prior quarter, alongside $10.7M in operating cash outflows. It completed an A$12.5M placement and A$3M share purchase plan, and expects its RAD101 Phase 3 trial to begin in 1Q27.

Confirmed

Global impact / market context

The completed share sales added funding that can support clinical programs, but operating outflows exceeded reported quarter-end cash. If spending continues at a similar pace, the company may need more funding or spending cuts; issuing shares can also reduce existing investors’ ownership percentages.

Analyst inference

The update combines financing with progress across several clinical programs: the company expects its lead program’s Phase 3 trial to begin in 1Q27, while other programs advanced in development. These milestones may direct spending toward trials, but the update also reports substantial operating cash use.

Analyst inference

What to watch

1. Watch whether the expected Phase 3 trial begins in 1Q27; a delay could defer a clinical milestone and extend spending before the company reports further trial progress. Analyst inference
2. Track later cash balances and operating outflows to assess whether the completed placement and share purchase plan support ongoing trials or more financing becomes necessary. Analyst inference
3. Look for further clinical results from the other programs; the update reported development advances but gave no efficacy figures or safety and efficacy results for the latest dosing cohort. Analyst inference

Evidence

• globenewswire.com